AI Therapeutics Stock

ai-therapeutics.comBioTechFounded: 2013Funding to Date: $98MM

AI Therapeutics is the developer of a deep learning platform designed to synthesize public and proprietary data on drugs and diseases and finds new indications for our library of new chemical entities.

Register for Details

For more details on financing and valuation for AI Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for AI Therapeutics.

Register Today

Team

Management Team

Henri Lichenstein Ph.D
President, CSO & Chief Executive Officer
Tian Xu Ph.D
Co-Founder & Scientific Advisor
Paul Beckett Ph.D
Senior Director of Drug Discovery
Jonathan Rothberg Ph.D
Co-Founder & Board Member

Board Members

George Rehm JD
Gregg Fergus
4Catalyzer
Jonathan Rothberg Ph.D

Other companies like AI Therapeutics in the BioTech sector

Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$1.3B
Sector
Last Round Est. Valuation
$3.1B
Sector
Last Round Est. Valuation
$5.81B
Sector
Last Round Est. Valuation
$1.2B
Sector
Last Round Est. Valuation
$1.6B
Sector
Last Round Est. Valuation
$1.61B

News

LAM Therapeutics, a Guilford, Conn.-based developer of drugs for cancer and rare diseases, closed $58M in Series C financing. The backers were not disclosed. The company intends to use the funds to advance its drugs. Led by Henri Lichenstein, Ph.D., and Dr. Tian Xu, LAM Therapeutics develops precision therapeutics and companion diagnostics for cancer and …